A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
Solid Tumors
DRUG: RC48-ADC
maximal tolerance dose (MTD) of RC48-ADC, Maximum-tolerated dose (MTD) was defined as the highest dose level at which no more than one of six patients experienced DLT during the DLT assessment window., DLT will be evaluated on 28 days of observation period|AEs, The drug safety was assessed by investigator(s) according to NCI-CTCAE v4.0, Estimated 2 years
Cmax, Maximum Observed Plasma Concentration, Estimated 2 years|AUC, Area Under Curve, Estimated 2 years|Tmax, Time for Cmax, Estimated 2 years
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive